Perrigo Riding High On Wall Street As ANDA Approvals Resume
This article was originally published in The Tan Sheet
Executive Summary
Perrigo's resolution of quality control problems - and the ANDA approvals that have followed - are drawing Wall Street enthusiasm as the firm's stock price surged almost 69% in the second quarter.
You may also be interested in...
Schering’s Lotrimin Ultra Only Rx-To-OTC Switch Of 2001
Schering-Plough's Lotrimin Ultra topical antifungal was the first Rx-to-OTC switch drug approved by FDA in 25 months and the only switch in 2001
Schering’s Lotrimin Ultra Only Rx-To-OTC Switch Of 2001
Schering-Plough's Lotrimin Ultra topical antifungal was the first Rx-to-OTC switch drug approved by FDA in 25 months and the only switch in 2001
Schering’s Lotrimin Ultra Only Rx-To-OTC Switch Of 2001
Schering-Plough's Lotrimin Ultra topical antifungal was the first Rx-to-OTC switch drug approved by FDA in 25 months and the only switch in 2001